

From: Hart, Mary
To: [DeBoer, Briana](#)
Cc: [Roberts, Mark](#); [Ullrich, Elizabeth](#); [Grant, Carl](#); [Ryan Fahey](#)
Subject: [External_Sender] RE: your email dated June 6, 2018
Date: Friday, June 08, 2018 8:10:55 AM
Attachments: [Amendment letter June 2018.pdf](#)

Per our phone conversation of 6/6/18, attached please find the response regarding decommissioning activities at the site.

Regards,
Mary

From: DeBoer, Briana <Briana.DeBoer@nrc.gov>
Sent: Wednesday, June 6, 2018 10:50 AM
To: Hart, Mary <mary.hart@bms.com>
Cc: Roberts, Mark <Mark.Roberts@nrc.gov>; Ullrich, Elizabeth <Elizabeth.Ullrich@nrc.gov>
Subject: your letter dated May 31, 2018

License No. 06-27843-02
Docket No. 030-29266
Control No. 608976

To: Mary C. Hart, RSO, Associate Director, EHS
From: Briana DeBoer, NRC

As discussed on June 6, 2018 via telephone call with Mary Hart, Bristol-Myers Squibb RSO, Ryan Fahey, DDES Project Manager, Mark Roberts, NRC, and Briana DeBoer, NRC, below are the questions we have regarding your request.

1. The Decommissioning Plan proposes initiation of decommissioning work the week of June 4th, 2018, and PCO-Chemistry is scheduled to stop use of radioactive material on July 13, 2018. Please confirm that, as we discussed, decontamination activities in the PCO-Chemistry suite will not commence until active work with radionuclides has been completed.
2. Based on a records review it appears radionuclides from previous license amendments (Chlorine-36 and Nickle-63) are not listed on Table 3.1. Based on our review, please confirm that you have not previously possessed Chlorine-36 and that any Nickle-63 sources, now generally licensed, will be dispositioned in accordance with any applicable requirements in 10 CFR 31.
3. Please describe the methodology for disposition of the Cesium-137 source listed on your license?

Thank you,

Briana DeBoer

Health Physicist
Decommissioning, ISFSI, and Reactor Health Physics Branch
USNRC Region 1 DNMS

Rec'd. in LAT - 06/11/2018

NNSS/RGNI MATERIALS-002

(610) 337-5370

This message (including any attachments) may contain confidential, proprietary, privileged and/or private information. The information is intended to be for the use of the individual or entity designated above. If you are not the intended recipient of this message, please notify the sender immediately, and delete the message and any attachments. Any disclosure, reproduction, distribution or other use of this message or any attachments by an individual or entity other than the intended recipient is prohibited.



Bristol-Myers Squibb

U.S. Pharmaceuticals
P. O. Box 5100
Wallingford, CT 06492

June 6, 2018

U.S. Nuclear Regulatory Commission
Region I
2100 Renaissance Boulevard, Suite 100
King of Prussia, PA 19406

Re: Bristol-Myers Squibb License No. 06-27843-02 Amendment

Listed below is the response to your request for additional information regarding the Decommissioning Plan for the Bristol-Myers Squibb facility, located at 5 Research Parkway, Wallingford, CT, 06492.

- Decommissioning of the active PCO-Chemistry labs will not commence until all work with radionuclides has been completed.
- This Facility has never possessed Chlorine-36.
- The Nickel-63 Gas Chromatograph is no longer in our possession. It was transferred to another facility in 2002.
- The Cesium-137 source listed on our license will be transferred to another BMS facility.

Sincerely,

Mary C. Hart, RSO
Associate Director, EHS
Bristol-Myers Squibb Company
5 Research Parkway
Wallingford, Ct 06492
mary.hart@bms.com
230-677-6071

Carl Grant
Site Director
Bristol-Myers Squibb Company
5 Research Parkway
Wallingford, Ct 06492
carl.grant@bms.com
203-677-7637